Answers are grounded in this paper and cite their sources.
This study demonstrates the synergistic effects of eugenol and sanguinarine on MCF-7 cells, suggesting potential therapeutic applications.
This study investigates the anticancer and antioxidant potential of a novel phytochemical combination of eugenol, a natural compound extracted from cloves, and Sanguinarine, a flavonoid from Sanguinaria canadensis. The synergistic interaction between eugenol and Sanguinarine was found to exhibit moderate cytotoxicity against MCF-7 cell lines, with an IC50 value of 147.2 μM, suggesting potential anti-cancer properties. The combination also demonstrated potent antioxidant activity, comparable to quercetin, in DPPH and H2O2 scavenging assays. The results suggest that the eugenol-Sanguinarine combination may have therapeutic applications in the prevention and treatment of oxidative stress-related diseases and cancer. Further studies are needed to fully elucidate the mechanisms of action and optimal dosing regimens. Overall, this study highlights the potential of combining natural compounds to create novel antioxidant and anti-cancer agents, and underscores the importance of continued research into the therapeutic properties of plant-derived compounds.
No takes yet. Share an insight, caveat, or question.
Sharma et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: